To assess potential medication effects, we examined expression levels of EGR1, TOB1, NR4A2, and ADM in MDD patients who were prescribed SSRIs at the time of death (MDD + SSRI) and in those who were not (MDD−). Here, TOB1 is linked to major depressive disorder.